Stem cell transplantation in Hodgkin lymphoma

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Patients with relapsed Hodgkin lymphoma (HL) often undergo salvage chemotherapy followed by high-dose therapy and autologous stem cell transplantation (HDT/ASCT).
• Randomized studies demonstrate that HDT/ASCT improves progression-free survival and freedom from treatment failure compared to conventional chemotherapy in relapsed refractory HL.
• However, these studies were not powered to establish a significant improvement in overall survival.

Purpose of the Study:

• To review the indications and outcomes of autologous and allogeneic stem cell transplantation (SCT) in patients with Hodgkin lymphoma.
• To discuss novel therapies for patients relapsing after HDT/ASCT as a bridge to allogeneic SCT.

Main Methods:

• Review of randomized studies comparing HDT/ASCT with conventional chemotherapy in relapsed refractory HL.
• Discussion of current treatment strategies and emerging therapies for relapsed HL post-HDT/ASCT.

Main Results:

• HDT/ASCT significantly improves progression-free survival and freedom from treatment failure in relapsed refractory HL.
• Overall survival benefits of HDT/ASCT compared to conventional chemotherapy were not definitively established in prior studies.
• Novel therapies are available for patients who relapse after HDT/ASCT, serving as a bridge to allogeneic SCT.

Conclusions:

• Autologous SCT is a key component of salvage therapy for relapsed HL, offering improved disease control.
• Allogeneic SCT, often preceded by novel therapies, represents an option for patients with multiply relapsed disease.
• Further research is needed to optimize SCT strategies and survival outcomes in HL.